Sandoz’s Biosimilars Rituximab and Etanercept are Recommended for Approval in Europe

On Friday, April 21, 2017, Sandoz announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sandoz’s biosimilars rituximab and etanercept in Europe. If approved, rituximab may be used in all indications of MabThera® and etanercept may be used in all indications of Enbrel®.

According to the Sandoz announcement, in addition to rituximab and etanercept, Sandoz plans to launch three more biosimilars in oncology and immunology across key geographies by 2020.